$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000107008122000011 Filed on February 22, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$165.2M	$538.6M	$118.9M
YoY Change	38.96%	41.45%	23.21%
Cost Of Revenue	$9.327M	$32.33M	$4.900M
YoY Change	90.35%	71.05%	40.0%
Gross Profit	$155.9M	$506.3M	$114.0M
YoY Change	36.76%	39.93%	22.71%
Gross Profit Margin	94.36%	94.0%	95.88%
Selling, General & Admin	$86.55M	$285.8M	$75.50M
YoY Change	14.63%	16.56%	18.9%
% of Gross Profit	55.51%	56.45%	66.23%
Research & Development	$149.8M	$540.7M	$118.0M
YoY Change	26.99%	13.2%	44.25%
% of Gross Profit	96.11%	106.8%	103.51%
Depreciation & Amortization	$18.81M	$64.13M	$12.40M
YoY Change	51.7%	47.47%	33.62%
% of Gross Profit	12.07%	12.67%	10.88%
Operating Expenses	$240.6M	$913.0M	$215.2M
YoY Change	11.8%	12.37%	27.18%
Operating Profit	-$84.73M	-$374.4M	-$96.37M
YoY Change	-12.08%	-13.28%	32.41%
Interest Expense	-$41.40M	-$86.02M	-$24.30M
YoY Change	70.38%	52.65%	341.82%
% of Operating Profit
Other Income/Expense, Net	-$12.48M	-$57.88M	$58.90M
YoY Change	-121.18%	-167.94%	425.89%
Pretax Income	-$138.6M	-$518.3M	-$61.70M
YoY Change	124.65%	28.64%	-7.91%
Income Tax	$4.657M	$5.561M	$12.60M
% Of Pretax Income
Net Earnings	-$143.3M	-$523.9M	-$74.35M
YoY Change	92.68%	19.57%	-4.28%
Net Earnings / Revenue	-86.71%	-97.27%	-62.53%
Basic Earnings Per Share		-$7.43
Diluted Earnings Per Share	-$2.027M	-$7.43	-$1.080M
COMMON SHARES
Basic Shares Outstanding	70.70M	70.47M	68.24M
Diluted Shares Outstanding		70.47M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$773.4M	$773.4M	$1.104B
YoY Change	-29.93%	-29.93%	60.75%
Cash & Equivalents	$189.7M	$189.7M	$208.8M
Short-Term Investments	$583.7M	$583.7M	$894.8M
Other Short-Term Assets	$54.68M	$54.68M	$39.50M
YoY Change	38.43%	38.43%	120.67%
Inventory	$15.86M	$15.86M	$18.70M
Prepaid Expenses
Receivables	$110.5M	$110.5M	$69.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$954.4M	$954.4M	$1.232B
YoY Change	-22.52%	-22.52%	58.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.59M	$130.0M	$33.83M
YoY Change	55.43%	9.99%	57.0%
Goodwill	$82.34M		$82.34M
YoY Change	0.0%		0.0%
Intangibles	$724.8M		$715.3M
YoY Change	1.33%		0.68%
Long-Term Investments
YoY Change
Other Assets	$46.50M	$46.50M	$60.60M
YoY Change	-23.27%	-23.27%	269.51%
Total Long-Term Assets	$983.7M	$983.7M	$976.5M
YoY Change	0.73%	0.73%	15.63%
TOTAL ASSETS
Total Short-Term Assets	$954.4M	$954.4M	$1.232B
Total Long-Term Assets	$983.7M	$983.7M	$976.5M
Total Assets	$1.938B	$1.938B	$2.208B
YoY Change	-12.24%	-12.24%	36.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.03M	$23.03M	$18.67M
YoY Change	23.4%	23.17%	80.79%
Accrued Expenses	$105.6M	$105.6M	$92.00M
YoY Change	14.81%	14.81%	31.43%
Deferred Revenue			$4.151M
YoY Change			-49.64%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$149.5M	$211.8M	$22.30M
YoY Change	570.58%	849.91%	11.5%
Total Short-Term Liabilities	$509.3M	$509.3M	$277.3M
YoY Change	83.66%	83.68%	17.59%
LONG-TERM LIABILITIES
Long-Term Debt	$281.9M	$976.6M	$309.1M
YoY Change	-8.81%	-1.44%	5.2%
Other Long-Term Liabilities	$313.5M	$313.5M	$1.392M
YoY Change	22422.92%	-2.42%	887.23%
Total Long-Term Liabilities	$281.9M	$1.290B	$310.5M
YoY Change	-9.22%	-1.68%	5.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$509.3M	$509.3M	$277.3M
Total Long-Term Liabilities	$281.9M	$1.290B	$310.5M
Total Liabilities	$1.937B	$1.937B	$1.726B
YoY Change	12.18%	12.18%	67.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.098B		-$1.629B
YoY Change	28.8%		36.82%
Common Stock	$71.00K		$70.00K
YoY Change	1.43%		12.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.438M	$1.438M	$482.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.938B	$1.938B	$2.208B
YoY Change	-12.24%	-12.24%	36.0%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$143.3M	-$523.9M	-$74.35M
YoY Change	92.68%	19.57%	-4.28%
Depreciation, Depletion And Amortization	$18.81M	$64.13M	$12.40M
YoY Change	51.7%	47.47%	33.62%
Cash From Operating Activities	-$68.84M	-$251.3M	-$64.36M
YoY Change	6.96%	29.51%	530.36%
INVESTING ACTIVITIES
Capital Expenditures	-$8.726M	$28.21M	-$6.350M
YoY Change	37.42%	58.12%	36.27%
Acquisitions
YoY Change
Other Investing Activities	$77.00M	$247.4M	-$201.8M
YoY Change	-138.16%	-145.5%	-10.06%
Cash From Investing Activities	$68.27M	$219.2M	-$208.1M
YoY Change	-132.81%	-139.03%	-9.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.354M	20.88M	40.09M
YoY Change	-89.14%	-96.88%	1658.33%
NET CHANGE
Cash From Operating Activities	-68.84M	-251.3M	-64.36M
Cash From Investing Activities	68.27M	219.2M	-208.1M
Cash From Financing Activities	4.354M	20.88M	40.09M
Net Change In Cash	3.788M	-19.09M	-232.4M
YoY Change	-101.63%	-75.9%	-1.92%
FREE CASH FLOW
Cash From Operating Activities	-$68.84M	-$251.3M	-$64.36M
Capital Expenditures	-$8.726M	$28.21M	-$6.350M
Free Cash Flow	-$60.11M	-$279.5M	-$58.01M
YoY Change	3.63%	31.91%	945.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-523901000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-438160000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-251576000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70466393
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66027908
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58863185
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.43
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.64
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.27
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70828226
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69718096
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35969
CY2021	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3416587
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Corporate Court
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South Plainfield,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07080
CY2021	dei	City Area Code CityAreaCode	908
CY2021	dei	Local Phone Number LocalPhoneNumber	222-7000
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	PTCT
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2191128010
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71362471
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208812000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	583658000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	894838000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	110455000
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	69929000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2020Q4	us-gaap	Inventory Net InventoryNet	18697000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	54681000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39469000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	954368000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1231745000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33831000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	724841000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	715328000
CY2021Q4	us-gaap	Goodwill Goodwill	82341000
CY2020Q4	us-gaap	Goodwill Goodwill	82341000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77421000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84410000
CY2021Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	46500000
CY2020Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	60623000
CY2021Q4	us-gaap	Assets Assets	1938056000
CY2020Q4	us-gaap	Assets Assets	2208278000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1628877000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1938056000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	242168000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	149540000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4151000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7273000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7465000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1276000
CY2021Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	59291000
CY2020Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	21023000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1460000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1250000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	509348000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	277333000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	281894000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	309145000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	239900000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	240400000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137110000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	136735000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73619000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	79499000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20053000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23053000
CY2021Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	674694000
CY2020Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	658739000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1392000
CY2021Q4	us-gaap	Liabilities Liabilities	1936618000
CY2020Q4	us-gaap	Liabilities Liabilities	1726296000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70828226
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69718096
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	71000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	70000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2123606000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2171746000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24282000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60957000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2097957000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2208278000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	538593000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380766000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	306980000
CY2021	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	32328000
CY2020	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	18942000
CY2019	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	12135000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54751000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36892000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27650000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	540684000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	477643000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	257452000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	285773000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	245164000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	202541000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	500000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-23280000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-48360000
CY2020	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000
CY2021	us-gaap	Operating Expenses OperatingExpenses	913036000
CY2020	us-gaap	Operating Expenses OperatingExpenses	812534000
CY2019	us-gaap	Operating Expenses OperatingExpenses	548138000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-374443000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-431768000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-241158000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-86022000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-56352000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12491000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57875000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	85188000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13723000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-518340000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-402932000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-239926000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5561000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35228000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11650000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-251576000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70466393
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66027908
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58863185
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.43
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.64
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.27
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-251576000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	165000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2502000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1145000
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	724000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39177000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-51518000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12770000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-487226000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-488533000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-263622000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	350727000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	323756000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	119482000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18276000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3577000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42134000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-251576000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12046000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	594330000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28092000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42869000
CY2020	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	70179000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5303000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70325000
CY2020	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	9107000
CY2020	us-gaap	Stockholders Equity Other StockholdersEquityOther	218000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-50373000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17309000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5792000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103513000
CY2021	ptct	Adjustments To Additional Paid In Capital Receivable From Investor AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor	483000
CY2021	us-gaap	Stockholders Equity Other StockholdersEquityOther	-25000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	36675000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1438000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523901000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-438160000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-251576000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64134000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	43490000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32180000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7386000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6084000
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3709000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41382000
CY2021	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	23460000
CY2020	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	2055000
CY2021	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	77683000
CY2020	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	31817000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-500000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	23280000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48360000
CY2020	ptct	Settlement Of Deferred And Contingent Consideration SettlementOfDeferredAndContingentConsideration	10613000
CY2020	ptct	Shares Issued Asset Acquisition SharesIssuedAssetAcquisition	42869000
CY2021	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-6078000
CY2020	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	14310000
CY2019	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	2194000
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-8281000
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	19252000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1673000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5299000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-409000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1922000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1848000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1020000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	694000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	103513000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	70325000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	42134000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	22598000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	12027000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-16000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-312000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	377000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5872000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8829000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-47391000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	56980000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	11619000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1800000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1841000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3456000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15310000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12621000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8835000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	44991000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	10483000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-11525000
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	232000
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	662000
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	484000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	45659000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	70798000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	26836000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6704000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3930000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3771000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4010000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8032000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1388000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-251332000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-194071000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98639000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28213000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17843000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13757000
CY2020	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	333148000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1439665000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	494068000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	210018000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	843498000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	944094000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	156270000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4281000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	57118000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	38134000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	31682000
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	100000
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4000000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	219182000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-561548000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-387237000
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	279267000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17309000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	70179000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18276000
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	597000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28092000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	323756000
CY2020	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	28333000
CY2019	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	11667000
CY2020	ptct	Payments On Deferred Consideration Obligation PaymentsOnDeferredConsiderationObligation	38100000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5792000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5303000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3577000
CY2021	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	2224000
CY2020	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	17829000
CY2020	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20877000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6717000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	668715000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	613209000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7821000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7688000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1303000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19094000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-79216000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	126030000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169498000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9588000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9802000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	7693000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7708000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26397000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2109000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2502000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1145000
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	724000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	645000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	76811000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17389000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41382000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	22294000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	14191000
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	11434000
CY2020	ptct	Stock Issued During Period Value Exchange Rights StockIssuedDuringPeriodValueExchangeRights	150528000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1060000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have few or no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes that this allows it to maximize value for all of its stakeholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) and Brazil for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. In July 2020, the European Commission approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (inotersen) and Waylivra<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company has initiated its commercial launch for Tegsedi for the treatment of hATTR amyloidosis in Brazil and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs. In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil, and the Company has initiated its commercial launch in Brazil while<span style="background:#ffffff;"> continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP programs</span>. Waylivra has also received marketing authorization in the EU for the treatment of FCS. Additionally, the Company submitted an application to ANVISA in December 2021 for the approval of Waylivra for the treatment of familial partial lipodystrophy, and it expects a regulatory decision on approval in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (risdiplam), which was approved by the United States Food and Drug Administration (“FDA”) in August 2020 for the treatment of SMA in adults and children two months and older and by the European Commission in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In January 2022, the FDA granted priority review of a supplemental new drug application for Evrysdi to expand the indication to include pre-symptomatic infants under two months old with SMA. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company announced the results from its Phase 1 study of PTC518 in healthy volunteers in September 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid and protein levels, that PTC518 efficiently crosses the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">blood brain barrier at significant levels and that PTC518 was well tolerated. The Company expects to initiate a Phase 2 study of PTC518 in the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In January 2020, the Company submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”) for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the Committee for Medicinal Products for Human Use (“CHMP”) in April 2022. The Company is also preparing a biologics license application (“BLA”) for PTC-AADC for the treatment of AADC deficiency in the United States. In response to discussions with the FDA, the Company intends to provide additional information concerning the use of the commercial cannula for PTC-AADC in young patients. The Company expects to submit a BLA to the FDA in the second quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and PTC857. The Company initiated a registration-directed Phase 2/3 placebo-controlled trial of vatiquinone in children with mitochondrial disease associated seizures in the third quarter of 2020. The Company has experienced delays in enrolling this trial due to the COVID-19 pandemic and now anticipates results from this trial to be available in the fourth quarter of 2022. The Company also initiated a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in the fourth quarter of 2020 and anticipates results from this trial to be available in the second quarter of 2023. In the third quarter of 2021, the Company completed a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. PTC857 was found to be well-tolerated with no reported serious adverse events while demonstrating predictable pharmacology. The Company expects to initiate a Phase 2 trial of PTC857 for amyotrophic lateral sclerosis in the second quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The most advanced molecule in the Company’s metabolic platform is PTC923, an oral formulation of synthetic sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. The Company initiated a registration-directed Phase 3 trial for PTC923 for phenylketonuria (“PKU”) in the third quarter of 2021 and expects results from this trial to be available by the end of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also has two oncology agents that are in clinical development, unesbulin and emvododstat. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company expects to initiate a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the second quarter of 2022, and it expects to initiate a registration-directed Phase 2 trial of unesbulin for the treatment of DIPG in the third quarter of 2022. The Company completed its Phase 1 trial evaluating emvododstat, a small molecule dihydrooratate dehydrogenase inhibitor that inhibits de novo pyrimidine nucleotide synthesis, in acute myelogenous leukemia (“AML”), in the fourth quarter of 2021. The Company expects to provide further updates regarding its emvododstat program at a later date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company initiated a Phase 2/3 clinical trial evaluating the efficacy and safety of emvododstat in patients hospitalized with COVID-19. In February 2021, the Company announced the completion of the first stage of the Phase 2/3 trial. The Company expects results from this trial to be available in the first half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. The marketing authorization in the EEA was last renewed in June 2021 and is effective, unless extended, through August 5, 2022. In February 2022, the Company submitted a marketing authorization renewal request to the EMA. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The Company refers to the trial and open-label extension together as Study 041. The Company expects results from the placebo-controlled trial to be available in mid-2022. The Company then expects to submit a report on the placebo-controlled trial and the open-label extension data that has been collected to date to the EMA by the end of the third quarter of 2022, as required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application (“NDA”) over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. <span style="background:#ffffff;">Study 045 did not meet its pre-specified primary endpoint. The Company expects results from the placebo-controlled trial of Study 041 to be available in mid-2022, and subject to a positive outcome in that study, the Company expects to re-submit the NDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had an accumulated deficit of approximately $2,098.0 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August 2015 of 3.00% convertible senior notes due 2022 (see Note 8), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, “at the market offering” of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), private placements of its convertible preferred stock, collaborations, bank and institutional lender debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</p>
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2098000000.0
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for the convertible notes, indefinite lived intangible assets annual impairment assessment, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189718000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208812000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	7500000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	7500000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197218000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9128000
CY2021Q4	us-gaap	Inventory Net InventoryNet	15856000
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist primarily of cash and cash equivalents, available-for-sale marketable securities and accounts receivable. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s investment policy includes guidelines on the quality of the financial institutions and financial instruments the Company is allowed to invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its accounts receivable related to its product sales. The payment terms are predetermined and the Company evaluates the creditworthiness of each customer or distributor on a regular basis. The Company reserves all uninsured amounts billed directly to a patient until the time of cash receipt as collectability is not reasonably assured at the time the product is received. To date, the Company has not incurred any material credit losses.</p>
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1418000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	824000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7721000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8745000
CY2020Q4	us-gaap	Inventory Net InventoryNet	18697000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2200000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	500000
CY2020	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020Q3	ptct	Assigned Royalty Payment Retained Percentage AssignedRoyaltyPaymentRetainedPercentage	0.57067
CY2021Q4	ptct	Revenue Recognition Milestone Potential Achievements RevenueRecognitionMilestonePotentialAchievements	300000000.0
CY2020	ptct	Deferred Payroll Tax Liability Cares Act DeferredPayrollTaxLiabilityCaresAct	1300000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax Period Increase Decrease TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease	41000000.0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	377287000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	107000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	709000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	376685000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	892938000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1975000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	75000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	894838000
CY2020	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2020	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	800000
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	700000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	673000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	256801000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	36000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4985000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	709000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	261786000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	75000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	260970000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	75000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	260970000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	221611000
CY2021Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	155074000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	588863000
CY2020Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	305975000
CY2020Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable	0
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79758000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	51893000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27173000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18062000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33831000
CY2021	us-gaap	Depreciation Depreciation	9400000
CY2020	us-gaap	Depreciation Depreciation	6600000
CY2019	us-gaap	Depreciation Depreciation	4700000
CY2021Q4	ptct	Number Of Operating Leases NumberOfOperatingLeases	3
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	3000000.0
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20100000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1300000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23100000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	21400000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	15300000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	6000000.0
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	16411000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	12368000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	4929000000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4361000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2448000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	694000000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	656000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	450000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	350000000
CY2021	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	21428000
CY2020	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	15266000
CY2019	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	5973000000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y10M13D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y5M26D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0891
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0886
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	13683000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	8462000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	4466000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2224000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	17829000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	776000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	171000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	645000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	76811000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17389000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	41382000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13443000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13068000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12343000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11221000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	3000000
CY2021Q4	ptct	Lessee Operating Lease Liability Payments Due Year Fiveand Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter	80771000
CY2021Q4	ptct	Finance Lease Liability Payments Due Year Five And After FinanceLeaseLiabilityPaymentsDueYearFiveAndAfter	21000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	130846000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	33000000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	49954000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	9947000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	80892000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	23053000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55733000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	53291000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1287000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4315000
CY2021Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	26434000
CY2020Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	18250000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3547000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3614000
CY2021Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	61662000
CY2020Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	54327000
CY2021Q4	ptct	Sales Rebates Current SalesRebatesCurrent	68770000
CY2020Q4	ptct	Sales Rebates Current SalesRebatesCurrent	63774000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	35679000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16575000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23033000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18665000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12639000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9357000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	288784000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	242168000
CY2020Q3	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000.0
CY2020Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.110
CY2020Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	679762000
CY2021	ptct	Liability Sale Of Future Royalties Royalty Revenue Payable LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable	23460000
CY2021	ptct	Liability Sale Of Future Royalties Interest Expense LiabilitySaleOfFutureRoyaltiesInterestExpense	77683000
CY2021Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	733985000
CY2021Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.109
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7563725
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	30.20
CY2019Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	224200000
CY2019Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2475248
CY2019Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	40.40
CY2019Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	97000000.0
CY2020	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	542470
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	53.37
CY2020	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	28100000
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-523901000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-438160000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-251576000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70466393
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66027908
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58863185
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.43
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.64
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.27
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12292413
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10645735
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11686358
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103513000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70325000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42134000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	198800000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M14D
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	ptct	Numberofdistributors Numberofdistributors	2
CY2020	ptct	Numberofdistributors Numberofdistributors	2
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4200000
CY2019	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	0
CY2020	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	0
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000000.0
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8100000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4200000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-487726000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-452475000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-231915000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-30614000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8011000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-518340000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	49543000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-402932000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-239926000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3844000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24984000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	61000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1340000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4372000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2041000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	377000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5872000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8812000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	736000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5561000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35228000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11650000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0074
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0331
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0108
CY2021	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0406
CY2020	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0666
CY2019	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0617
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0450
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0493
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0438
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2903
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2640
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3549
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	0.1205
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	0.0293
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	0.1589
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0072
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0188
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0146
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0367
CY2021	ptct	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositionsPercent	0.0478
CY2020	ptct	Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositionsPercent	0.0061
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0012
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0107
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0874
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0486
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	137110000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	136735000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	137110000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	136735000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8208000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5528000
CY2021Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	87998000
CY2020Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	80677000
CY2021Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	142595000
CY2020Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	123405000
CY2021Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	8054000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	76589000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	16999000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	9159000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1428000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	3316000
CY2021Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	241000
CY2020Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	661000
CY2020Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	7624000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	526119000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	412138000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15273000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14612000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	148503000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	549000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	161204000
CY2021Q4	ptct	Deferred Tax Assets Noncash Interest Expense DeferredTaxAssetsNoncashInterestExpense	26040000
CY2021Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	143000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525570000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	379608000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	32530000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	549000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2904000
CY2020Q4	ptct	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	29626000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	137110000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	136735000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	137659000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	169265000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	137110000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	136735000
CY2021	ptct	Taxable Income Before Net Operating Loss TaxableIncomeBeforeNetOperatingLoss	306900000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3800000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525600000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	379600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	146000000.0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	112500000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	114600000
CY2021Q4	ptct	Deferred Tax Assets Operating Loss Carryforwards Limitedby Irc Section382 DeferredTaxAssetsOperatingLossCarryforwardsLimitedbyIRCSection382	231500000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	169200000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	62300000
CY2020	ptct	Operating Loss Carryforwards Utilized OperatingLossCarryforwardsUtilized	364100000
CY2021	ptct	Operating Loss Carryforwards In Next Twelve Months OperatingLossCarryforwardsInNextTwelveMonths	5700000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27200000
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	48000000.0
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2446000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	24771000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27217000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	24800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	100000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Assets Assets	1938056000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52585000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	538593000
CY2020Q4	us-gaap	Assets Assets	2208278000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33831000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380766000
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6600000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5300000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54800000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36900000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27700000
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0

Files In Submission

Name	View Source	Status
0001070081-22-000011-index-headers.html	Edgar Link	pending
0001070081-22-000011-index.html	Edgar Link	pending
0001070081-22-000011.txt	Edgar Link	pending
0001070081-22-000011-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptct-20211231.xsd	Edgar Link	pending
ptct-20211231ex1044a6165.htm	Edgar Link	pending
ptct-20211231ex1044a6165001.jpg	Edgar Link	pending
ptct-20211231ex10539db78.htm	Edgar Link	pending
ptct-20211231ex231998366.htm	Edgar Link	pending
ptct-20211231ex3117bbdd3.htm	Edgar Link	pending
ptct-20211231ex312249d1b.htm	Edgar Link	pending
ptct-20211231ex321934f76.htm	Edgar Link	pending
ptct-20211231ex322ac4ecc.htm	Edgar Link	pending
ptct-20211231ex41769a2d9.htm	Edgar Link	pending
ptct-20211231x10k.htm	Edgar Link	pending
ptct-20211231x10k006.jpg	Edgar Link	pending
ptct-20211231x10k_htm.xml	Edgar Link	completed
ptct-20211231_cal.xml	Edgar Link	unprocessable
ptct-20211231_def.xml	Edgar Link	unprocessable
ptct-20211231_lab.xml	Edgar Link	unprocessable
ptct-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2021 Q4 Form 10-K Financial Statement

#000107008122000011 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2021 Q4 Form 10-K Financial Statement

#000107008122000011 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct